Miach Orthopaedics Names Jamal Rushdy President and CEO 

Longtime medtech veteran Jamal Rushdy has been chosen to lead Miach Orthopaedics Inc. as president and CEO, succeeding Patrick McBrayer, the company announced today. He will officially move into the corner office on May 18.

McBrayer is stepping down from the role under a planned leadership transition conducted in partnership with the Board of Directors. McBrayer will remain president and CEO until Rushdy begins his tenure.

“Patrick joined Miach at a pivotal moment, as we were accelerating commercialization of the BEAR Implant,” Miach Orthopaedics Chair and Amzak Health Managing Partner Joyce Erony stated. “Under his leadership, the company has established a strong presence in ACL restoration, with the BEAR Implant now used by more than 750 surgeons to treat over 9,000 patients. Jamal is the right person to build on that foundation and guide Miach through its next phase of growth.” 

Rushdy has nearly 30 years of experience in the medical device industry, with deep expertise in orthopedics, sports medicine, and regenerative medicine. He most recently was CEO of Arcuro Medical and previously led Collagen Solutions. Over the course of his career, he has raised significant operating capital and led organizations across various stages of growth, from early-stage ventures to high-growth established companies. He has also held senior leadership roles at Tornier and DJO (now Enovis) and was a founding executive of three medtech companies with multiple successful exits.

“Miach has built strong momentum with differentiated technology and compelling clinical evidence behind the BEAR Implant,” Rushdy said. “The opportunity now is to expand use and advance new indications, with the goal of helping people with ACL tears return to an active lifestyle while preserving long-term knee health. I’m excited to work with the Miach team and the orthopedic community to bring the benefits of the BEAR Implant to even more people, and I thank Patrick for his support.”

McBrayer joined Miach in 2022 and played a pivotal role in strengthening the company’s foundation and positioning it for growth. During his tenure, Miach secured more than $60 million in funding, expanded commercial adoption of the Bridge-Enhanced ACL Restoration (BEAR) Implant, and achieved U.S. Food and Drug Administration approval of key label updates to enable use in children and adolescents of any age and for partial anterior cruciate ligament (ACL) tears, as well as to include reduced risk of developing radiographically confirmed post-traumatic osteoarthritis (PTOA). He also helped build the company’s executive leadership team and shape its culture during his successful tenure. 

“Miach is entering its next chapter with strong momentum, and it has been an honor to lead the company’s efforts to transform the treatment of ACL tears over the past several years,” McBrayer said. “What this team has accomplished, from bringing the BEAR Implant into broader clinical use to expanding its adoption among surgeons, has been incredibly meaningful. I’m beyond proud of what this team has built and excited about the impact Miach will continue to have in the years ahead.”

The BEAR Implant is the first disruptive technology in ACL tear treatment in more than 30 years. The implant enables a torn ACL to heal and restores the knee’s natural function. It is a paradigm shift from the current care standard—reconstruction that replaces the ACL with a graft. 

Miach Orthopaedics Inc. is a privately held company based in Westborough, Mass., that develops surgical implants to facilitate connective tissue restoration. The company’s initial focus is the BEAR Implant, which represents a paradigm shift in ACL tear treatment.